Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
COVID vaccine news dominates our last monthly round-up of articles from Springer Nature research journals, magazines and supplements of the year. The articles explore how the many vaccines in development are affecting the pharmaceutical sector and what challenges lie ahead for their rollout.
After a decade of uncertainty, a trio of clinical trial successes in 2020 is spurring enthusiasm about the potential for effectively treating disease via manipulation of the gut microbiome.
The maturation of oligonucleotide and gene therapies, and the birth of the gene editing revolution, are spurring innovation in the cardiovascular and metabolic disease space.
In our second monthly digest of ‘business of science’ articles from Springer Nature research journals, magazines and supplements, we delve into the history of cystic fibrosis research, celebrate two Nobel prize–winning CRISPR gene editing pioneers and examine big pharma’s interest in antibody–drug conjugates and exosomes.
In the first of a new monthly digest, we highlight recent ‘business of science’ articles from Springer Nature research journals, magazines and supplements. This digest looks at the latest drugs approved by the US FDA and a $1bn antibody development deal, peeps into the Chan Zuckerberg Biohub, and offers advice to budding science entrepreneurs.
Last year saw an uptick in medtech mergers and acquisitions values, whereas financing declined. This year is bringing new opportunities and challenges for the field as it responds to the demands of the coronavirus.
The market for drugs to treat central nervous system disorders is set for growth, supported by the continued strength of therapies for multiple sclerosis.
Optimization of CAR-T cell technology and application of other immune cell types such as NK cells are tackling the efficacy, cost and logistical challenges of cell therapies for cancer.
The next-generation therapeutics space has continued to progress on several fronts in the past 12 months, but this could be set to change as the industry copes with the COVID‑19 crisis.
While dealmaking in oncology continued to feature immunotherapies—particularly multi-targeted agents—there was also diversification, with prominent deals for precision medicine and novel platform technologies.
The complement pathway’s intricate network of proteins, which have a key role in the innate immune system, are attracting dealmakers’ attention as targets for a variety of inflammatory diseases.